Related Experiment Videos
Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study
T van Joost1, F Heule, M Korstanje
1Department of Dermatology, University Hospital Rotterdam-Dijkzigt, The Netherlands.
The British Journal of Dermatology
|May 1, 1994
Summary
Cyclosporin significantly improved severe atopic dermatitis symptoms over six weeks. This immunosuppressant medication demonstrated superior efficacy compared to placebo, with most patients showing substantial disease reduction.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Severe atopic dermatitis poses a significant challenge in dermatological treatment.
- Existing therapies may have limitations in efficacy or safety for severe cases.
- Cyclosporin is an immunosuppressant with potential applications in inflammatory skin conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of cyclosporin in patients with severe atopic dermatitis.
- To compare cyclosporin treatment against a placebo in a double-blind, controlled study.
Main Methods:
- A double-blind, placebo-controlled study involving 46 patients with severe atopic dermatitis.
- Patients received either cyclosporin (5 mg/kg daily) or a placebo for six weeks.
- Disease severity (TBSA) and extent (RoNAA) were assessed using standardized scoring systems.
Main Results:
- Significantly fewer patients discontinued due to inefficacy in the cyclosporin group (17%) compared to placebo (61%).
- Cyclosporin treatment led to a 55% improvement in disease severity (TBSA) and a 40% improvement in disease extent (RoNAA).
- While transient increases in creatinine and bilirubin were observed with cyclosporin, all values normalized post-treatment, and blood pressure remained stable.
Conclusions:
- Cyclosporin is a safe and highly effective treatment for severe atopic dermatitis episodes.
- Strict adherence to administration guidelines is crucial for optimal outcomes and safety.
- The study confirms cyclosporin's role in managing severe inflammatory skin conditions.